| Literature DB >> 33390724 |
I Putu Eka Widyadharma1, Ni Nyoman Shinta Prasista Sari2, Kadek Enny Pradnyaswari2, Kadek Tresna Yuwana2, I Putu Gede Danika Adikarya2, Clarissa Tertia1, I A Sri Wijayanti1, I A Sri Indrayani1, Desak Ketut Indrasari Utami1.
Abstract
Coronavirus disease 2019 (COVID-19) is a current global pandemic. The case number has increased since December 31, 2019. It has been reported that COVID-19 patients have been giving pain complaints, one of which is muscular pain. Other types of pain that have also been reported by COVID-19 patients are joint pain, stomach pain, and testicular pain. Neuropathic pain is the rarest case among others. COVID-19 mechanisms in the nerve and musculoskeletal damage are believed to be caused by the expression and distribution of angiotensin-converting enzyme 2 (ACE-2). Patients with pain, especially neuropathic pain, normally do not respond well to various therapies, and experience psychiatric disorders such as depression, which leads to a decrease in the patient's quality of life. Important considerations for health professionals in terms of pain management during this pandemic include ensuring treatment continuity, painkillers, utilization of telemedicine, biopsychosocial management approach, and modifying therapy needs to reduce the risks of COVID-19 complications.Entities:
Keywords: COVID-19; Management; Muscular pain; Neuropathic pain
Year: 2020 PMID: 33390724 PMCID: PMC7767578 DOI: 10.1186/s41983-020-00258-0
Source DB: PubMed Journal: Egypt J Neurol Psychiatr Neurosurg ISSN: 1110-1083